Save The Date!
VPM & TWINCORE Joint Symposium | Sep 15-16, 2022 | Hannover
This year the 14th TWINCORE Symposium and the 13th International VPM Days, celebrating VPM's 20th Anniversary, have taken place as a joint symposium "Lessons from the pandemic for future infection research" on Thursday and Friday, 15 and 16 September 2022 in Hannover, Germany.
Press
Results of SAKK 06/14 trial with VPM1002BC
SAVE THE DATE!
VPM & TWINCORE Joint Symposium | Sep 15-16, 2022 | Hannover
Press
Results of SAKK 06/14 trial with VPM1002BC
The phase I/II clinical trial data with VPM1002BC, a genetically modified bacillus Calmette-Guérin (BCG) strain, has been published in European Urology Oncology. Even three years after the treatment start, almost half of the patients remained recurrence-free. We thank all patients, colleagues, and collaborators for their contributions.
A competent partner at your side
Free first consulting session
We understand how complexe product development is, because we did it ourselves. Let us be a competent partner at your side for a secure route to a successful product.
From Bench to Product
Consulting and services
A competent partner at your side
Free first consulting session
From Bench to Product
Consulting and services
Speed up your development processes by using our expertise. We offer a comprehensive service portfolio covering all stages of pharmaceutical development.
About Vakzine Projekt Management
VPM offers tailor-made consultancy and services based on in-depth experience in development of biopharmaceutical candidates. As a client, you will benefit from the experience of our team in translational project management. This enables you to bring your development projects into clinical trials faster, more cost-effectively and with a higher probability of success.
The company was established in 2002. Within the last decade, VPM has successfully managed and consulted the development of promising biopharmaceutical candidates, ranging from small molecules, recombinant proteins up to gene-modified live vaccines and ATMPs. VPM brought these products for its customers in the pharmaceutical industry, academic research and small biotechnology companies, from preclinical phase through clinical phases I-III.
News & Press
VPM celebrated its 20 year anniversary during the joint symposium organized by TWINCORE and VPM.
We are very proud to be able to welcome more than 100 participants at TWINCORE in Hannover!. Read more.
Article about VPM’s tuberculosis (TB) vaccine published in the Frankfurter Rundschau
An article about our tuberculosis (TB) vaccine has been published in the “Frankfurter Rundschau”. For more info click here.
Tuberculosis vaccine candidate VPM1002 safe in HIV- and non-HIV-exposed newborns as study shows
A clinical trial in South Africa has now shown that the new vaccine candidate VPM1002, developed by Max Planck researcher Stefan H.E. Kaufmann and his team, is equally safe for newborns with and without HIV exposure and has fewer side effects compared to BCG. Please click here to read the publication.
